Senseonics (NYSE:SENS) Now Covered by StockNews.com

Research analysts at StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a research report issued on Tuesday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Senseonics in a research note on Wednesday, August 14th.

Senseonics Stock Performance

NYSE SENS opened at $0.35 on Tuesday. The stock has a market capitalization of $185.01 million, a PE ratio of -2.49 and a beta of 0.79. The business has a 50 day simple moving average of $0.37 and a two-hundred day simple moving average of $0.42. The company has a debt-to-equity ratio of 59.17, a current ratio of 3.11 and a quick ratio of 2.89. Senseonics has a 1-year low of $0.32 and a 1-year high of $0.75.

Senseonics (NYSE:SENS) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $4.87 million during the quarter, compared to analysts’ expectations of $4.86 million. Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. On average, research analysts predict that Senseonics will post -0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Senseonics

Several institutional investors have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System bought a new stake in shares of Senseonics during the 1st quarter worth approximately $91,000. Virtu Financial LLC bought a new stake in shares of Senseonics during the 1st quarter worth approximately $162,000. Cubist Systematic Strategies LLC lifted its stake in shares of Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after acquiring an additional 85,501 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after acquiring an additional 51,000 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Senseonics by 30.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after acquiring an additional 211,128 shares during the last quarter. 12.36% of the stock is owned by institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.